BioLineRx announced that the United States Patent and Trademark Office granted a Notice of Allowance for its investigational small‑molecule GLIX1 under application serial 18/602,969. The patent, titled “Deoxy‑Cytidine or Uridine Derivatives for Use in Cancer Therapies,” protects the use of GLIX1 in cancers that do not over‑express cytidine deaminase (CDA) beyond a defined threshold, covering more than 90 % of all cancer types. The allowance extends protection through 2040, with a potential five‑year term extension, and is supported by pending international filings that could extend exclusivity to 2044 for combination claims with PARP inhibitors.
The expanded IP footprint gives BioLineRx a robust legal foundation for pursuing GLIX1 across a wide array of solid tumors. By securing rights in the majority of cancers, the company can launch a first‑in‑human study in glioblastoma in Q1 2026 and subsequently explore other indications without infringing on third‑party patents. The allowance also positions BioLineRx to attract strategic partners or licensing agreements, as the strong exclusivity window enhances the commercial attractiveness of GLIX1.
CEO Philip Serlin emphasized the strategic value of the patent: “This Notice of Allowance is a critical addition to GLIX1’s intellectual‑property estate, protecting our opportunity to evaluate this molecule across the majority of cancers. As we prepare to initiate a first‑in‑human study of GLIX1 in glioblastoma in the first quarter of 2026, we are advancing pre‑clinical studies in other cancer models, confident that GLIX1’s unique mechanism of action offers new hope for patients with difficult‑to‑treat cancers.”
Financially, BioLineRx reported a net loss of $5.8 million on $4.9 million in revenue for Q3 2024, and a net loss of $3.9 million on $0.3 million in revenue for Q2 2025. The company’s cash runway is projected to extend into the first half of 2027, underscoring the importance of securing IP that can support future clinical milestones and potential commercial partnerships.
Following the announcement, BioLineRx’s shares rose 2 % on the day, driven by the market’s recognition that the expanded patent coverage significantly strengthens the long‑term value and commercial potential of GLIX1 across a broad spectrum of cancers. The reaction reflects investor confidence that the robust IP estate will underpin future development and partnership opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.